Focus on CNS Drug Development Treating secondary progressive multiple sclerosis. Simon Wilkinson, CEO

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Focus on CNS Drug Development Treating secondary progressive multiple sclerosis. Simon Wilkinson, CEO"

Transcription

1 Focus on CNS Drug Development Treating secondary progressive multiple sclerosis Simon Wilkinson, CEO

2 Forward Looking Statements 2 This Presentation (and any financial information that may be provided by Innate Immunotherapeutics Limited - the Company ) may contain forward looking statements that involve risks and uncertainties. Such statements include statements regarding the Company s belief or current expectation and are necessarily based on the Company s current understanding of the markets and industries in which it operates. That understanding could change or could prove to be inconsistent with actual developments. The Company s actual results could differ materially from the results discussed in this Presentation, including those anticipated in or implied by any forward looking statements.

3 What is multiple sclerosis? (Source: MedicineNet, Inc) The myelin sheath protecting the nerve fibers inside the CNS is damaged by a likely combination of both autoimmune and neuro degenerative processes This triggers inflammatory pathology that causes further damage In early disease, myelin is fully or partially repaired Over time, scar-like plaque builds up around damaged axons inhibiting repair 3

4 Is Multiple Sclerosis and CNS disease? 4 Until recently most market discussions about multiple sclerosis have focused on the early stage relapsing-remitting course of the disease. In early MS, relapses are largely mediated by auto-reactive proinflammatory adaptive immune cells crossing the blood brain barrier and attacking the myelin sheath an autoimmune process or disease. In spite of drugs designed to block, or sequester, or divert such autoimmune activity, within 20 years ~70% of RRMS patients transition to a progressive stage of disease where deficits steadily accumulate in the absence of relapses and existing RRMS drugs become ineffective. Progressive MS is now largely viewed as a neurodegenerative disorder. The pathologic role of myeloid derived innate immune cells in neurodegenerative disorders is well understood. However we now know that both macrophages and microglia can also play vital roles limiting inflammation & promoting tissue repair in CNS disorders including progressive MS.

5 Myeloid cells play an important role in CNS disorders 5 This myeloid cell bi-polar behaviour is essential so that an immune response can adapt according to the stage, severity, location, & type of disease. Peripherally derived macrophages, and the CNS equivalent microglia cells, can be activated or polarised towards either a M1 inflammatory phenotype or a M2 anti-inflammatory phenotype. In addition to being anti-inflammatory within the CNS, M2 macrophages and microglia have been shown to: support myelin repair by clearing myelin debris 1. secrete important tropic factors that can directly promote neuronal survival and axon regeneration 2,3,4. 1. Kotter MR et al Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. J. Neurosci. 26, Butovsky O et al., Microglia activated by IL-4 or IFN-gamma differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells. Molec. Cell. Neurosci. 31, Rolls A et al., 2008.Two faces of chondroitin sulfate proteoglycan in spinal cord repair: a role in microglia/macrophage activation. PLoS Med. 5, e Kuo HS et al., Acid fibroblast growth factor and peripheral nerve grafts regulate Th2 cytokine expression, macrophage activation, polyamine synthesis, and neurotrophin expression in transected rat spinal cords. J. Neurosci. 31,

6 The Journal of Neuroscience, July 8, (27): Significance Statement There is a growing appreciation that macrophages exert diverse functions in the injured and diseased CNS. Indeed, both macrophage-mediated repair and macrophage-mediated injury occur, and often these effector functions are elicited simultaneously. Understanding the mechanisms governing the reparative and pathological properties of activated macrophages is at the forefront of neuroscience research.

7 Introducing MIS416 a MYELOID targeting immune modulator 7 MIS416 is a highly purified microparticle derived from the naturally occurring bacteria P. acnes MIS416 reliably, safely, and uniquely targets myeloid cells MIS416 targeted myeloid cells: Increase in number switch activity from pathogenic to reparative traffic into the CNS (past the blood brain barrier) The targeted cells have an anti-inflammatory effect inside the CNS and have also been shown to: support myelin repair by clearing myelin debris MIS x 0.5 micron rod shaped microparticle secrete important tropic factors that can directly promote neuronal survival and axon regeneration

8 MIS416 effect on cellular and soluble anti-inflammatory pathways 8 Tolerogenic DC Bone marrow-derived monocyte Alternate/non classical/m2 macrophage IL-10 TGFb IL-27 stnfr PDL-1?? Arginase IDO IL-12p70 IL-1b TNFa MHC I/II CD80/86 NO sil-1r Anti-inflammatory/tolerance mechanisms Pro-inflammatory mechanisms Upregulation following MIS416 treatment: in Mouse in Human under investigation?

9 MIS416 effect on tropic factors associated with CNS protection/repair 9 VEGF (pg/ml) Vascular Endothelial Factor Baseline (pre-treatment) 24 hr post dose sample number (arbitary) EPO (pg/ml) Erythropoietin pre-treatment 24 hr post dose sample number (arbitary) A selection of phase 1B and 2A patient plasma samples were analysed to screen for the induction of factors associated with neuroprotection. IGF-1 (pg/ml) Insulin Growth Factor-1 Baseline (pre-treatment) 24 hr post dose HGF (pg/ml) Hepatocyte Growth Factor (Baseline) pre-treatment 24 hr post dose Data are shown from examples that showed a clear response for a given factor Samples are assigned arbitrary sample numbers sample number (arbitary) sample number (arbitary)

10 Phase 2B trial in SPMS a clinical Proof of Platform 10 Double blinded, placebo controlled 12 month trial of MIS416 in 90 patients 2:1 randomisation, once weekly 500 mcg i.v. injection of MIS416 or saline Baseline, quarterly, and end of dosing (EoD) clinical assessments including: Hand/arm function & strength, cognition, visual acuity, fatigue, MSFC and EDSS Patient reported outcomes: SF-36, pain (BPI), and fatigue (NFI-MS) Baseline, month 3 & EoD MRI (whole brain atrophy and magnetization transfer ratio) 45 patients (50% of the target 90 patients) are now enrolled, consented or in washout period (for previous RRMS drugs) enrolment is on going

11 MIS416 - A CNS REPAIR PLATFORM 11 Turning off inflammation, removing tissue debris, supplying repair and protective factors, are all criterial functions of the innate immune system relative to repairing tissue damage inside the CNS, whether the damage is caused by trauma or certain diseases. The presence of inflammation inside the CNS, as a consequence of certain other diseases, can amplify disease damage and/or lessen the effectiveness of disease modifying therapies. Activating the regulatory functions of the innate immune system to switch off inflammation inside the CNS makes sense especially when anti-inflammatory drugs can t cross the blood-brain barrier and access the CNS! If MIS416 works in patients with SPMS, a disease where there is both tissue damage (the myelin) and ongoing inflammation inside the CNS, then MIS416 becomes a platform to be used in other conditions or diseases requiring these critical CNS repair tools Further announcements can be expected within the next 8-12 weeks

12 Post Phase 2B path to market for SPMS 12 There are no effective drugs approved to treat SPMS Approval of a drug for SPMS could be reviewed under FDA s Expedited Programs for Serious Conditions Pharma with existing drugs for early stage MS (RRMS) are actively seeking drugs to treat SPMS Biogen s RRMS drug Tecfidera sold US$3b in 2014 following approval part way through 2013 Upon completion of Phase 2B (2016) Innate s strategy is to license / sell to large Pharma company Potential Target Partners or Acquirers

13 Post Phase 2B path to market for SPMS 13 What does a partnering deal look like in SPMS? December 2014: Servier paid US$47 million option fee to fund Phase 2B trial of GeNeuro s blocking antibody to supposed MS-associated retrovirus Received option to the non-us territorial rights tied to a $408 million package of milestones N.B. The non-us territory accounts for about ~25% of global MS drug revenues Also option buy an equity stake sometime in 2015 See announcement: < LATE BREAKING NEWS Celgene to acquire Phase 3 MS company Receptos for US$7.2 billion cash Deal has ranked Receptos #1 for the most value created by any biotech in the last 10 years.

14 Thank you Two clinical trial patients talk about their ongoing experience with MIS416: Simon Wilkinson, CEO or tel Australian Securities Exchange (ASX) ticker - IIL

Bioshares Investment Summit Presentation

Bioshares Investment Summit Presentation ABN 16 165 160 841 ASX RELEASE 20 JULY 2015 Bioshares Investment Summit Presentation Innate Immunotherapeutics' CEO Mr. Simon Wilkinson gave a presentation (attached) at the 2015 Bioshares Investment Summit

More information

A Phase 2 company treating Secondary Progressive Multiple Sclerosis. April 2016

A Phase 2 company treating Secondary Progressive Multiple Sclerosis. April 2016 A Phase 2 company treating Secondary Progressive Multiple Sclerosis April 2016 Forward Looking Statements This Presentation (and any financial information that may be provided by Innate Immunotherapeutics

More information

A Phase 2B company treating Secondary Progressive Multiple Sclerosis. Annual General Meeting - August 2014

A Phase 2B company treating Secondary Progressive Multiple Sclerosis. Annual General Meeting - August 2014 A Phase 2B company treating Secondary Progressive Multiple Sclerosis Annual General Meeting - August 2014 Forward Looking Statements This Presentation (and any financial information that may be provided

More information

A Phase 2 company treating Secondary Progressive Multiple Sclerosis. March 2015

A Phase 2 company treating Secondary Progressive Multiple Sclerosis. March 2015 A Phase 2 company treating Secondary Progressive Multiple Sclerosis March 2015 Forward Looking Statements This Presentation (and any financial information that may be provided by Innate Immunotherapeutics

More information

OHTAC Recommendation

OHTAC Recommendation OHTAC Recommendation Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency Presented to the Ontario Health Technology Advisory Committee in May 2010 May 2010 Issue Background A review on the

More information

Multiple Sclerosis. Matt Hulvey BL A - 615

Multiple Sclerosis. Matt Hulvey BL A - 615 Multiple Sclerosis Matt Hulvey BL A - 615 Multiple Sclerosis Multiple Sclerosis (MS) is an idiopathic inflammatory disease of the central nervous system (CNS) MS is characterized by demyelination (lesions)

More information

THERAPEUTIC ROLE OF IL-37 IN SPINAL CORD INJURY. Rubén López Vales Faculty of Medicine, UAB (Universitat Autònoma de Barcelona)

THERAPEUTIC ROLE OF IL-37 IN SPINAL CORD INJURY. Rubén López Vales Faculty of Medicine, UAB (Universitat Autònoma de Barcelona) THERAPEUTIC ROLE OF IL-37 IN SPINAL CORD INJURY Rubén López Vales Faculty of Medicine, UAB (Universitat Autònoma de Barcelona) 1. Summary Inflammatory response plays an essential role in protecting the

More information

Understanding How Existing and Emerging MS Therapies Work

Understanding How Existing and Emerging MS Therapies Work Understanding How Existing and Emerging MS Therapies Work This is a promising and hopeful time in the field of multiple sclerosis (MS). Many new and different therapies are nearing the final stages of

More information

The Prospect of Stem Cell Therapy in Multiple Sclerosis. Multiple sclerosis is a multifocal inflammatory disease of the central

The Prospect of Stem Cell Therapy in Multiple Sclerosis. Multiple sclerosis is a multifocal inflammatory disease of the central The Prospect of Stem Cell Therapy in Multiple Sclerosis Multiple sclerosis is a multifocal inflammatory disease of the central nervous system that generally affects young individuals, causing paralysis

More information

CAMBRIDGE UNIVERSITY CENTRE FOR BRAIN REPAIR A layman's account of our scientific objectives What is Brain Damage? Many forms of trauma and disease affect the nervous system to produce permanent neurological

More information

The Immunopathogenesis of Relapsing MS

The Immunopathogenesis of Relapsing MS The Immunopathogenesis of Relapsing MS Olaf Stüve, M.D., Ph.D. Neurology Section VA North Texas Health Care System Dallas VA Medical Center Departments of Neurology and Neurotherapeutics University of

More information

New Treatment Options for MS Patients: Understanding risks versus benefits

New Treatment Options for MS Patients: Understanding risks versus benefits New Treatment Options for MS Patients: Understanding risks versus benefits By Michael A. Meyer, MD Department of Neurology, Sisters Hospital, Buffalo, NY Objectives: 1. to understand fundamentals of MS

More information

Programa Cooperación Farma-Biotech Neurociencias NT-KO-003

Programa Cooperación Farma-Biotech Neurociencias NT-KO-003 Programa Cooperación Farma-Biotech Neurociencias NT-KO-003 A new oral treatment for Multiple Sclerosis based on a novel mechanism of action Barcelona, 15 de febrero 2011 Programa Cooperación Farma-Biotech

More information

A Letter From the MS Coalition

A Letter From the MS Coalition 0 A Letter From the MS Coalition The treatment of multiple sclerosis (MS) requires a comprehensive management strategy. One important component of that strategy is modifying the disease course. When deciding

More information

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

More information

Laquinimod Polman, C. et al. Neurology 2005;64:987-991

Laquinimod Polman, C. et al. Neurology 2005;64:987-991 Laquinimod Polman, C. et al. Neurology 2005;64:987-991 Multicenter, double-blind, randomized trial, patients with RR MS received 0.1 mg or 0.3 mg laquinimod or placebo as three daily tablets for 24 weeks

More information

Clinical Trials of Disease Modifying Treatments

Clinical Trials of Disease Modifying Treatments MS CENTER CLINICAL RESEARCH The UCSF MS Center is an internationally recognized leader in multiple sclerosis clinical research. We conduct clinical trials involving the use of experimental treatments,

More information

New research in primary and secondary progressive multiple sclerosis. Dr Claire McCarthy MRCP PhD Neurology SpR Addenbrooke s Hospital

New research in primary and secondary progressive multiple sclerosis. Dr Claire McCarthy MRCP PhD Neurology SpR Addenbrooke s Hospital New research in primary and secondary progressive multiple sclerosis Huntingdon MS Society Annual Meeting Sat 22nd March 2014 Dr Claire McCarthy MRCP PhD Neurology SpR Addenbrooke s Hospital 1 Overview

More information

Issues Regarding Use of Placebo in MS Drug Trials. Peter Scott Chin, MD Novartis Pharmaceuticals Corporation

Issues Regarding Use of Placebo in MS Drug Trials. Peter Scott Chin, MD Novartis Pharmaceuticals Corporation Issues Regarding Use of Placebo in MS Drug Trials Peter Scott Chin, MD Novartis Pharmaceuticals Corporation Context of the Guidance The draft EMA Guidance mentions placebo as a comparator for superiority

More information

RELAPSE MANAGEMENT. Pauline Shaw MS Nurse Specialist 25 th June 2010

RELAPSE MANAGEMENT. Pauline Shaw MS Nurse Specialist 25 th June 2010 RELAPSE MANAGEMENT Pauline Shaw MS Nurse Specialist 25 th June 2010 AIMS OF SESSION Relapsing/Remitting MS Definition of relapse/relapse rate Relapse Management NICE Guidelines Regional Clinical Guidelines

More information

Understanding. Multiple Sclerosis. Tim, diagnosed in 2004.

Understanding. Multiple Sclerosis. Tim, diagnosed in 2004. Understanding Multiple Sclerosis Tim, diagnosed in 2004. What Is Multiple Sclerosis? Multiple sclerosis (MS) is a neurologic disorder that affects the central nervous system (CNS). The CNS includes the

More information

BN201: a paradigm-shift (neuroprotection) in the treatment of neurodegenerative diseases

BN201: a paradigm-shift (neuroprotection) in the treatment of neurodegenerative diseases Programa Cooperación Farma-Biotech 9º encuentro (4 de julio de 2013) BN201: a paradigm-shift (neuroprotection) in the treatment of neurodegenerative diseases Barcelona, 4 de julio de 2013 Programa Cooperación

More information

Psychology 3625 Cellular and Molecular Neuroscience. Dr Darren Hannesson

Psychology 3625 Cellular and Molecular Neuroscience. Dr Darren Hannesson Psychology 3625 Cellular and Molecular Neuroscience Dr Darren Hannesson Lecture 6 Cells of the nervous system Neurons Glia Other cell types Blood-brain barrier Types of nervous system cells Neurons The

More information

Effets biologiques des facteurs de croissance sur la régénération musculaire

Effets biologiques des facteurs de croissance sur la régénération musculaire Effets biologiques des facteurs de croissance sur la régénération musculaire Xavier Bigard (MD, PhD) Professeur Agrégé du Val-de-Grâce Institut de Recherche Biomédicale des Armées (IRBA) La Tronche (Grenoble)

More information

New perception of disability including cognition, fatigue, pain and other impairments related to MS

New perception of disability including cognition, fatigue, pain and other impairments related to MS New perception of disability including cognition, fatigue, pain and other impairments related to MS Diego Cadavid, MD Director, MS Clinical Development Biogen Idec 1 Need for clarity on terminology for

More information

Disease Modifying Therapies for MS

Disease Modifying Therapies for MS Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks

More information

IF YOU ARE RECEIVING TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS (NATALIZUMAB)

IF YOU ARE RECEIVING TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS (NATALIZUMAB) IF YOU ARE RECEIVING (NATALIZUMAB) TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS Read the patient information leaflet that accompanies the medicine carefully. 1 This brochure is a supplement to the

More information

Disease Modifying Therapies for MS

Disease Modifying Therapies for MS Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks

More information

AUBMC Multiple Sclerosis Center

AUBMC Multiple Sclerosis Center AUBMC Multiple Sclerosis Center 1 AUBMC Multiple Sclerosis Center The vision of the American University of Beirut Medical Center (AUBMC) is to be the leading academic medical center in Lebanon and the

More information

What is Multiple Sclerosis? Gener al information

What is Multiple Sclerosis? Gener al information What is Multiple Sclerosis? Gener al information Kim, diagnosed in 1986 What is MS? Multiple sclerosis (or MS) is a chronic, often disabling disease that attacks the central nervous system (brain and spinal

More information

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market

A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies NEC3-52 November 2014 Contents

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Daclizumab for treating relapsing-remitting multiple Draft scope (pre-referral) Draft remit/appraisal objective To

More information

- Patients treated with alemtuzumab in CARE-MS II were more than twice as likely to experience disability improvement compared to Rebif -

- Patients treated with alemtuzumab in CARE-MS II were more than twice as likely to experience disability improvement compared to Rebif - PRESS RELEASE Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received Lemtrada TM* (Alemtuzumab) Compared With Rebif in Phase lll Trial - Patients treated with

More information

FastTest. You ve read the book... ... now test yourself

FastTest. You ve read the book... ... now test yourself FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to

More information

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer

FORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2011

More information

My MS prog-blog. The ezine for people with progressive MS Issue 2, June/ July 2015

My MS prog-blog. The ezine for people with progressive MS Issue 2, June/ July 2015 My MS prog-blog The ezine for people with progressive MS Issue 2, June/ July 2015 Hello and welcome to the second edition of my new free ezine for progressive MSers. My name is Ian Cook. I m an MSer from

More information

Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA

Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA Media Release Basel, 28 June 2016 Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA OCREVUS is the first investigational medicine

More information

Committee Approval Date: December 12, 2014 Next Review Date: December 2015

Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January

More information

Managing Relapsing Remitting MS Risks & benefits of emerging therapies. Dr Mike Boggild The Walton Centre

Managing Relapsing Remitting MS Risks & benefits of emerging therapies. Dr Mike Boggild The Walton Centre Managing Relapsing Remitting MS Risks & benefits of emerging therapies Dr Mike Boggild The Walton Centre MS: Facts and figures Affects 1 in 800 in the UK Commonest cause of acquired neurological disability

More information

Vitamin D deficiency exacerbates ischemic cell loss and sensory motor dysfunction in an experimental stroke model

Vitamin D deficiency exacerbates ischemic cell loss and sensory motor dysfunction in an experimental stroke model Vitamin D deficiency exacerbates ischemic cell loss and sensory motor dysfunction in an experimental stroke model Robyn Balden & Farida Sohrabji Texas A&M Health Science Center- College of Medicine ISC

More information

Top Ten Things to Know About Stem Cell Treatments

Top Ten Things to Know About Stem Cell Treatments Top Ten Things to Know About Stem Cell Treatments Many clinics that are offering stem cell treatments make claims about what stem cells can and cannot do that are not supported by our understanding of

More information

J.P. Morgan Cazenove Therapeutic Seminar

J.P. Morgan Cazenove Therapeutic Seminar Jannan, MS J.P. Morgan Cazenove Therapeutic Seminar David Meeker - CEO, Genzyme June 25, 2012 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private

More information

Natalizumab (Tysabri)

Natalizumab (Tysabri) Natalizumab (Tysabri) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Natalizumab (Tysabri) Date of issue: July 2010 Review date: July 2011 Contents Section

More information

AUBAGIO (teriflunomide) oral tablet

AUBAGIO (teriflunomide) oral tablet AUBAGIO (teriflunomide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

GENENTECH S OCRELIZUMAB FIRST INVESTIGATIONAL MEDICINE TO SHOW EFFICACY IN PEOPLE WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS IN LARGE PHASE III STUDY

GENENTECH S OCRELIZUMAB FIRST INVESTIGATIONAL MEDICINE TO SHOW EFFICACY IN PEOPLE WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS IN LARGE PHASE III STUDY NEWS RELEASE Media Contact: Tara Iannuccillo (650) 467-6800 Investor Contacts: Stefan Foser Karl Mahler (650) 467-2016 011 41 61 687 8503 GENENTECH S OCRELIZUMAB FIRST INVESTIGATIONAL MEDICINE TO SHOW

More information

Innate Host Defenses Graphics are used with permission of Pearson Education Inc., publishing as Benjamin Cummings (http://www.aw-bc.com).

Innate Host Defenses Graphics are used with permission of Pearson Education Inc., publishing as Benjamin Cummings (http://www.aw-bc.com). Innate Host Defenses Graphics are used with permission of Pearson Education Inc., publishing as Benjamin Cummings (http://www.aw-bc.com). Page 1: Introduction Surface barriers (the skin, mucous membranes,

More information

Conflict of Interest Declaration. Overview of New Medications for Multiple Sclerosis. Assessment Question. Objectives 4/1/2011

Conflict of Interest Declaration. Overview of New Medications for Multiple Sclerosis. Assessment Question. Objectives 4/1/2011 Conflict of Interest Declaration Overview of New Medications for Multiple Sclerosis I or my spouse have no actual or potential conflict of interest in relation to this activity. Crystal Obering, Pharm.D.,

More information

A blood sample will be collected annually for up to 2 years for JCV antibody testing.

A blood sample will be collected annually for up to 2 years for JCV antibody testing. Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:

More information

Understanding your Tecfidera treatment

Understanding your Tecfidera treatment Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. (dimethyl fumarate) Contents About Multiple Sclerosis (MS) What is MS? Symptoms of MS

More information

Understanding your Tecfidera treatment

Understanding your Tecfidera treatment Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. (dimethyl fumarate) Contents About Multiple Sclerosis (MS) What is MS? Symptoms of MS

More information

Recent Multiple Sclerosis (MS)

Recent Multiple Sclerosis (MS) neuroscience Promoting Remyelination and Preventing Demyelination New Research Goals in Finding a Therapy for Multiple Sclerosis Priya Rajgopal 11 24 Recent Multiple Sclerosis (MS) research has made it

More information

Personalised Medicine in MS

Personalised Medicine in MS Personalised Medicine in MS Supportive Evidence from Therapeutic Trials Ludwig Kappos Neurology and Department of Biomedicine University Hospital CH-4031 Basel LKappos@uhbs.ch Established partially effective

More information

Chapter 10. Summary & Future perspectives

Chapter 10. Summary & Future perspectives Summary & Future perspectives 123 Multiple sclerosis is a chronic disorder of the central nervous system, characterized by inflammation and axonal degeneration. All current therapies modulate the peripheral

More information

A neurologist would assess your eligibility and suitability for the DMTs.

A neurologist would assess your eligibility and suitability for the DMTs. Choices Disease Modifying Treatments Disease modifying treatments (DMTs) are medications which modify the disease course. They target inflammation and are designed to reduce the damage caused by relapses.

More information

Neurological Disorders

Neurological Disorders Neurological Disorders Grades 9-12 Driving Question: In what ways do neurological impairments affect brain function? Objectives: Students will be able to Describe how migraines, Alzheimer s disease, and

More information

The Types of stem cells: Totipotent Pluripotent Multipotent

The Types of stem cells: Totipotent Pluripotent Multipotent Stem Cells is the main material for building and regeneration of the body Stem cells are not differentiated and can transform to any cell of organism Stem cells are capable of indefinite renewal through

More information

A Definition of Multiple Sclerosis

A Definition of Multiple Sclerosis English 182 READING PRACTICE by Alyx Meltzer, Spring 2009 Vocabulary Preview (see bolded, underlined words) gait: (n) a particular way of walking transient: (adj) temporary; synonym = transitory remission:

More information

Collaborative Network Award Planning Grants Project Summaries

Collaborative Network Award Planning Grants Project Summaries Collaborative Network Award Planning Grants Project Summaries PRIORITY AREA: Projects that will drive development of one or more pre-clinical drug candidates through identification and validation of molecular

More information

Summary HTA. Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C. HTA-Report Summary

Summary HTA. Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C. HTA-Report Summary Summary HTA HTA-Report Summary Interferons and Natalizumab for Multiple Sclerosis Clar C, Velasco-Garrido M, Gericke C Health policy background Multiple sclerosis (MS) is a chronic inflammatory disease

More information

Cytokines pattern of Multiple Sclerosis patients treated with Apitherapy

Cytokines pattern of Multiple Sclerosis patients treated with Apitherapy Cytokines pattern of Multiple Sclerosis patients treated with Apitherapy Ahmad G. Hegazi, Khaled Al- Menabbawy, Eman H. Abd El- Rahman and Suzette I. Helal National Research Center, Dokki, Giza, Egypt

More information

Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis

Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis T Kozák, P Lhotáková Department of Clinical Haematology, 3r d School of Medicine,

More information

Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS?

Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS? Marie Trad, M.D., Lynne Hughes, Cathy VanBelle, Amy Del Medico 3rd International

More information

ANIMALS FORM & FUNCTION BODY DEFENSES NONSPECIFIC DEFENSES PHYSICAL BARRIERS PHAGOCYTES. Animals Form & Function Activity #4 page 1

ANIMALS FORM & FUNCTION BODY DEFENSES NONSPECIFIC DEFENSES PHYSICAL BARRIERS PHAGOCYTES. Animals Form & Function Activity #4 page 1 AP BIOLOGY ANIMALS FORM & FUNCTION ACTIVITY #4 NAME DATE HOUR BODY DEFENSES NONSPECIFIC DEFENSES PHYSICAL BARRIERS PHAGOCYTES Animals Form & Function Activity #4 page 1 INFLAMMATORY RESPONSE ANTIMICROBIAL

More information

Hyperbaric Oxygen Treatment for Multiple Sclerosis Patients

Hyperbaric Oxygen Treatment for Multiple Sclerosis Patients Hyperbaric Oxygen Treatment for Multiple Sclerosis Patients The first MS Therapy Centre opened in Dundee in August 1982 and now there are over 100 chambers in operation in 64 MS Therapy Centres distributed

More information

the Bank Statement The UK Multiple Sclerosis Tissue Bank

the Bank Statement The UK Multiple Sclerosis Tissue Bank the Bank Statement ISSUE 1 A newsletter for you In this issue, find out about What does the Tissue Bank do? News from The UK Multiple Sclerosis Tissue Bank Welcome to our first newsletter, designed with

More information

CBT IN THE CITY. adjusted to the news of being with MS? April 2013. Experts at your fingertips call now. Check out our new services in you local area

CBT IN THE CITY. adjusted to the news of being with MS? April 2013. Experts at your fingertips call now. Check out our new services in you local area April 2013 Experts at your fingertips call now CBT IN THE CITY Check out our new services in you local area contents. A message from Susie, Information Multiple Sclerosis CBT can make a difference on the

More information

PAR Joint Health. Inflammation and Joint

PAR Joint Health. Inflammation and Joint PAR ARACTIN Joint Health Inflammation and Joint Arthritis affects more than 7 million Americans. Arthritis is a disease that results in inflammation, pain and stiffness, primarily in the joints and connective

More information

An introduction to modern MS treatments

An introduction to modern MS treatments BETAFERON is a Prescription Medicine. Use strictly as directed. Consult your pharmacist or other health professional in case of side effects. BETAFERON is reimbursed for some patients. See your neurologist

More information

MS Research Summaries 2009. MS Society of Canada

MS Research Summaries 2009. MS Society of Canada MS Research Summaries 2009 MS Society of Canada CONTENTS BIOMEDICAL RESEARCH GRANTS 3 CLINICAL AND POPULATION HEALTH RESEARCH GRANTS 21 FOUNDATION AWARDS 25 DONALD PATY CAREER DEVELOPMENT AWARDS 32 POST-DOCTORAL

More information

PCORI Workshop on Treatment for Multiple Sclerosis. Breakout Group Topics and Questions Draft 3-27-15

PCORI Workshop on Treatment for Multiple Sclerosis. Breakout Group Topics and Questions Draft 3-27-15 PCORI Workshop on Treatment for Multiple Sclerosis Breakout Group Topics and Questions Draft 3-27-15 Group 1 - Comparison across DMTs, including differential effects in subgroups Consolidated straw man

More information

How to S.E.A.R.C.H. SM for the Right MS Therapy For You!

How to S.E.A.R.C.H. SM for the Right MS Therapy For You! How to S.E.A.R.C.H. SM for the Right MS Therapy For You! The Changing Landscape The first treatment for relapsing-remitting multiple sclerosis (RRMS) was approved by the United States Food and Drug Administration

More information

Demystifying Stem Cells. Brent Bost M.D., CPA, MBA, FACOG

Demystifying Stem Cells. Brent Bost M.D., CPA, MBA, FACOG Demystifying Stem Cells Brent Bost M.D., CPA, MBA, FACOG Disclaimers Author currently serves on Board of Directors of CordTrack Most applications discussed today are not currently FDA approved and are,

More information

The Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences

The Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences The Nuts and Bolts of Multiple Sclerosis Rebecca Milholland, M.D., Ph.D. Center for Neurosciences Objectives Discuss which patients are at risk for Multiple Sclerosis Discuss the diagnostic criteria for

More information

Media Release. Basel, 8 October 2015

Media Release. Basel, 8 October 2015 Media Release Basel, 8 October 2015 Roche s ocrelizumab first investigational medicine to show positive pivotal study results in both relapsing and primary progressive forms of multiple sclerosis Ocrelizumab

More information

National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook

National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers

More information

IMMUNOLOGY STRUCTURE AND FUNCTION OF IMMUNE SYSTEM

IMMUNOLOGY STRUCTURE AND FUNCTION OF IMMUNE SYSTEM 59 IMMUNOLOGY STRUCTURE AND FUNCTION OF IMMUNE SYSTEM 59.1 INTRODUCTION The immune system is engaged in a constant surveillance of the body for pathogens or tumors. Whether disease develops depends on

More information

AMPYRA (dalfampridine) Important Safety Information

AMPYRA (dalfampridine) Important Safety Information NEWS RELEASE Acorda to Present New rhigm22 and AMPYRA (dalfampridine) Data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 10/7/2015 ARDSLEY, N.Y.--(BUSINESS

More information

MS Treatments Aubagio TM

MS Treatments Aubagio TM 1 MSology Essentials Series Aubagio TM (teriflunomide) Developed by MSology with the invaluable assistance of multiple sclerosis nurse advisors: Bonnie Blain Central Alberta MS Clinic, Red Deer, Alberta

More information

Progress in MS: Current and Emerging Therapies

Progress in MS: Current and Emerging Therapies Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC The MS Society gratefully acknowledges the grant received from Biogen Idec Canada, which makes possible the

More information

Aetiology and Pathology of Periodontal Disease. Dr. Wendy Turner

Aetiology and Pathology of Periodontal Disease. Dr. Wendy Turner Aetiology and Pathology of Periodontal Disease Dr. Wendy Turner Lecture Outline Periodontal structures and the inflammatory response Periodontal disease progression stages Pathogenesis and the host response

More information

Molecular Pathology of MS: Signposts to new Therapy Hans Lassmann (MD)

Molecular Pathology of MS: Signposts to new Therapy Hans Lassmann (MD) Brain Research Center Medical University of Vienna Molecular Pathology of MS: Signposts to new Therapy Hans Lassmann (MD) IMMUNOLOGY OF MULTIPLE SCLEROSIS Noseworthy et al 2000 NEJM Immunomodulatory Treatment

More information

A Genetic Analysis of Rheumatoid Arthritis

A Genetic Analysis of Rheumatoid Arthritis A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.

More information

A Case for Cure: Drug Portfolio Analysis. Team: PharmaKings Anirvan Chaudhuri Neha Madan Xiao Huang Jason Park Anjai Lal

A Case for Cure: Drug Portfolio Analysis. Team: PharmaKings Anirvan Chaudhuri Neha Madan Xiao Huang Jason Park Anjai Lal A Case for Cure: Drug Portfolio Analysis Team: PharmaKings Anirvan Chaudhuri Neha Madan Xiao Huang Jason Park Anjai Lal Executive Summary Our team recommends. A Recombinant Protein for treatment of Multiple

More information

CAN-FITE BIOPHARMA LTD.

CAN-FITE BIOPHARMA LTD. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month

More information

XENOPORT INC FORM 8-K. (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14

XENOPORT INC FORM 8-K. (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14 XENOPORT INC FORM 8-K (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14 Address 3410 CENTRAL EXPRESSWAY SANTA CLARA, CA 95051 Telephone 4086167200 CIK 0001130591 Symbol XNPT SIC Code

More information

NEW DIRECTION IN THE IMPROVEMENT OF CLINICAL CONDITIONS IN MULTIPLE SCLEROSIS PATIENTS By F. De Silvestri, E. Romani, A. Grasso

NEW DIRECTION IN THE IMPROVEMENT OF CLINICAL CONDITIONS IN MULTIPLE SCLEROSIS PATIENTS By F. De Silvestri, E. Romani, A. Grasso NEW DIRECTION IN THE IMPROVEMENT OF CLINICAL CONDITIONS IN MULTIPLE SCLEROSIS PATIENTS By F. De Silvestri, E. Romani, A. Grasso Introduction Multiple sclerosis (MS), in its many and varied clinical forms,

More information

The MS Disease- Modifying Drugs. Gener al information

The MS Disease- Modifying Drugs. Gener al information The MS Disease- Modifying Drugs Gener al information Current as of October 30, 2009. This online version is updated as breaking news requires. If you have downloaded and printed a copy from the web, please

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 15 September 2005 Doc. Ref. EMEA/CHMP/EWP/561/98 Rev 1 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT

More information

Drug Development Services

Drug Development Services Drug Development Services USING BLOOD AND BONE MARROW PRIMARY CELL SYSTEMS Clinically Relevant In Vitro Assays Broad Spectrum of Drug Classes Multi-Species Platforms Enhancing Drug Development through

More information

STEM CELL FELLOWSHIP

STEM CELL FELLOWSHIP Module I: The Basic Principles of Stem Cells 1. Basics of Stem Cells a. Understanding the development of embryonic stem cells i. Embryonic stem cells ii. Embryonic germ cells iii. Differentiated stem cell

More information

GOLD INDUCED CYTOKINES

GOLD INDUCED CYTOKINES GOLD INDUCED CYTOKINES BACKGROUND / INTRODUCTION In the late stage, degenerative age-related alterations can lead to destruction and loss of function in the affected tissue structures and can be accompanied

More information

Autoimmunity. Autoimmunity. Genetic Contributions to Autoimmunity. Targets of Autoimmunity

Autoimmunity. Autoimmunity. Genetic Contributions to Autoimmunity. Targets of Autoimmunity Autoimmunity Factors predisposing an individual to autoimmune disease Mechanisms of initiation of autoimmunity Pathogenesis of particular autoimmune disease Animal models of autoimmune disease Treatment

More information

Autoimmunity and immunemediated. FOCiS. Lecture outline

Autoimmunity and immunemediated. FOCiS. Lecture outline 1 Autoimmunity and immunemediated inflammatory diseases Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline Pathogenesis of autoimmunity: why selftolerance fails Genetics of autoimmune diseases Therapeutic

More information

Immune System. Daryl Beatty Brazosport College Anatomy & Physiology II

Immune System. Daryl Beatty Brazosport College Anatomy & Physiology II Immune System Daryl Beatty Brazosport College Anatomy & Physiology II 21 The Immune System: Innate and Adaptive Body Defenses Which of the following best describes the immune system? a. the set of organs

More information

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis Your contact News Release Barbara Fry Phone +1 905 919 0163 April 29/30, 2009 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple

More information

Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON

Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON First-line DMTs Reduce Relapse Frequency by ~30% vs. Placebo Frequency of relapse with various DMTs, based

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency London, 16 November 2006 Doc. Ref. CPMP/EWP/561/98 Rev. 1 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS FOR THE

More information

CNS DEMYLINATING DISORDERS

CNS DEMYLINATING DISORDERS CNS DEMYLINATING DISORDERS Multiple sclerosis A Dutch saint named Lidwina, who died in 1433, may have been one of the first known MS patients. After she fell while ice skating, she developed symptoms such

More information

Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study

Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study Nele Claes 1 *; Tessa Dhaeze 1 *; Judith Fraussen PhD 1 ; Bieke Broux

More information

Dr Paul Turner. Research Scientist Dunedin

Dr Paul Turner. Research Scientist Dunedin Dr Paul Turner Research Scientist Dunedin Spinal Cord Society NZ Inc. Who: Aim: Started by Noela & Keith Vallis & people with spinal cord injury (SCI), their families and care-givers in 1988. To support

More information